The DOI matches its Crossref record; 15 of the 23 references it cites were found in a registry or an index, and 8 are not checked yet.
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Abstract
Purpose: The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance. Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented. Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology. Patients and Methods: In this study, we performed a comprehensive gene expression analysis on 152 human samples including prostate cancer tissues, prostate tissues adjacent to tumor, and organ donor prostate tissues, obtained from men of various ages, using the Affymetrix (Santa Clara, CA) U95a, U95b, and U95c chip sets (37,777 genes and expression sequence tags). Results: Our results confirm an alteration of gene expression in prostate cancer when comparing with nontumor adjacent prostate tissues. However, our study also indicates that the gene expression pattern in tissues adjacent to cancer is so substantially altered that it resembles a cancer field effect. Conclusion: We also found that gene expression patterns can be used to predict the aggressiveness of prostate cancer using a novel model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Classical and Modern Regression With Applications.
Steinhorst, R. K., & Myers, R. H. (1988) · Journal of the American Statistical Association · doi:10.2307/2288958 · Cited by 3,690
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Cited by
Items 401–500 of 761
Magi‐Galluzzi, C., Maddala, T., Falzarano, S. M., Cherbavaz, D. B., Zhang, N., Knezevic, D., Febbo, P. G., Lee, M., Lawrence, H. J., & Klein, E. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8944 · Cited by 29
Oh, S., Shin, S., Song, H., Grande, J. P., & Janknecht, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44685-3 · Cited by 26
Methylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer
Mazzu, Y. Z., Yoshikawa, Y., Nandakumar, S., Chakraborty, G., Armenia, J., Jehane, L. E., Lee, G. M., & Kantoff, P. W. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12536 · Cited by 26
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer
Kido, T., Hatakeyama, S., Οhyama, C., & Lau, Y. C. (2010) · Genes · doi:10.3390/genes1020283 · Cited by 27
Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma
Güneş, A., Bağırsakçı, E., İşcan, E., Cakan‐Akdogan, G., Aykutlu, U., Şentürk, Ş., Özhan, G., Erdal, E., Nart, D., Yılmaz, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26402 · Cited by 25
Liu, S., Garcia-Marques, F. J., Zhang, C. A., Lee, J. J., Nolley, R., Shen, M., Hsu, E., Aslan, M., Koul, K., Pitteri, S. J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87155-5 · Cited by 26
Detection of fusion gene transcripts in the blood samples of prostate cancer patients
Yu, Y., Liu, S., Nelson, J. B., & Luo, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-96528-9 · Cited by 25
Self-citationVäänänen, R., Lilja, H. G., Kauko, L., Helo, P., Kekki, H., Cronin, A. M., Vickers, A. J., Nurmi, M. J., Alanen, K. A., Bjartell, A. S., et al. (2014) · Urology · doi:10.1016/j.urology.2013.11.005 · Cited by 25
Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression
Zhao, H., Logothetis, C. J., & Gorlov, I. P. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.9 · Cited by 25
Rubicz, R. C., Zhao, S., Wright, J. L., Coleman, I. M., Grasso, C. S., Geybels, M. S., Leonardson, A. S., Kolb, S., April, C., Bibikova, M. V., et al. (2016) · Molecular Oncology · doi:10.1002/1878-0261.12014 · Cited by 26
Koushyar, S., Economides, G., Zaat, S., Jiang, W. G., Bevan, C. L., & Dart, D. A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.32 · Cited by 25
Liang, Z., Cao, J., Tian, L., Shen, Y., Xu, Y., Lin, Q., Zhang, R., Liu, H., Du, X., Shi, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.001 · Cited by 27
Huang, D., Casale, G. P., Tian, J., Wehbi, N. K., Abrahams, N. A., Kaleem, Z., Smith, L. M., Johansson, S. L., Elkahwaji, J. E., & Hemstreet, G. P. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0718 · Cited by 25
Patel, A. A., Gilbertson, J. R., Showe, L. C., London, J., Ross, E. A., Ochs, M. F., Carver, J. R., Lazarus, A., Parwani, A. V., Dhir, R., et al. (2007) · Cancer Informatics · doi:10.1177/117693510700300002 · Cited by 25
Self-citationEpithelial protein lost in neoplasm (EPLIN): Beyond a tumor suppressor
Wu, D. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.03.002 · Cited by 24
Chen, J., Xu, D., Wang, T., Yang, Z., Yang, Y., He, K., & Zhao, L. (2022) · Oncology Reports · doi:10.3892/or.2022.8412 · Cited by 25
Hennigs, J. K., Müller, J., Adam, M., Spin, J. M., Riedel, E., Graefen, M., Bokemeyer, C., Sauter, G., Huland, H., Schlomm, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100469 · Cited by 24
Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression
Li, Y., Vongsangnak, W., Chen, L., & Shen, B. (2014) · BMC Medical Genomics · doi:10.1186/1755-8794-7-s1-s3 · Cited by 24
Bii, V. M., Collins, C. P., Hocum, J. D., & Trobridge, G. D. (2018) · Oncotarget · doi:10.18632/oncotarget.24503 · Cited by 24
Gologan, A., Bastacky, S., McHale, T., Yu, J., Cai, C. Y. L., Monzon, F. A., & Dhir, R. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180855.66948.5e · Cited by 24
Self-citationGenomic Profiling of Hormone-Naïve Lymph Node Metastases in Patients with Prostate Cancer
Paris, P. L., Hofer, M. D., Albo, G., Kuefer, R., Gschwend, J. E., Hautmann, R. E., Fridyland, J., Simko, J. P., Carroll, P. R., Rubin, M. A., et al. (2006) · Neoplasia · doi:10.1593/neo.06421 · Cited by 24
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer
Sørensen, K. D., Borre, M., Orntoft, T. F., Dyrskjøt, L., & Tørring, N. (2007) · International Journal of Cancer · doi:10.1002/ijc.23136 · Cited by 24
Dehmer, M., Mueller, L. A. J., & Emmert‐Streib, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077602 · Cited by 23
The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
Tian, L., Peng, Y., Yang, K., Cao, J., Du, X., Liang, Z., Shi, J., & Zhang, J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00979-0 · Cited by 23
Zhang, X., Li, H., Wang, Y., Zhao, H., Wang, Z., & Chan, F. L. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06621-w · Cited by 23
Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer
Makwana, V., Rudrawar, S., & Anoopkumar‐Dukie, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166129 · Cited by 24
Chen, Y., Zhang, Q., Wang, Q., Li, J., Sipeky, C., Xia, J., Gao, P. H., Hu, Y., Zhang, H., Yang, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04731-4 · Cited by 23
Store-Operated Ca2+ Entry as a Prostate Cancer Biomarker — a Riddle with Perspectives
Kappel, S., Marques, I. J., Zoni, E., Stokłosa, P., Peinelt, C., Mercader, N., Julio, M. K., & Borgström, A. (2017) · Current Molecular Biology Reports · doi:10.1007/s40610-017-0072-8 · Cited by 22
Miao, W., Yuan, J. J., Li, L., & Wang, Y. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b01561 · Cited by 23
A CD24‐p53 axis contributes to African American prostate cancer disparities
Liu, W., Zhang, Y., Wei, S., Bae, S., Yang, W., Smith, G. J., Mohler, J. L., Fontham, E. T. H., Bensen, J. T., Sonpavde, G., et al. (2020) · The Prostate · doi:10.1002/pros.23973 · Cited by 22
Anti-Breast Cancer Activity of Essential Oil: A Systematic Review
Mustapa, M. A., Guswenrivo, I., Zuhrotun, A., Ikram, N. K. K., & Muchtaridi, M. (2022) · Applied Sciences · doi:10.3390/app122412738 · Cited by 22
Chen, B., Liu, C., Long, H., Bai, G., Zhu, Y., & Xu, H. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5464 · Cited by 22
Death receptor 5 expression is inversely correlated with prostate cancer progression
Hernandez-Cueto, A., Hernández-Cueto, D., Antonio-Andrés, G., Mendoza-Marin, M., Jiménez-Gutiérrez, C., Sandoval-Mejia, A. L., Mora-Campos, R., González-Bonilla, C. R., Vega, M. I., Bonavida, B., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2504 · Cited by 22
Jacobs, D., Mao, Y., Fu, A., Kelly, W. K., & Zhu, Y. L. (2013) · BMC Urology · doi:10.1186/1471-2490-13-37 · Cited by 24
Tpl2 induces castration resistant prostate cancer progression and metastasis
Lee, H. W., Cho, H. J., Lee, S. J., Song, H. J., Cho, H. J., Park, M., Seol, H. J., Lee, J., Kim, S., Lee, H. M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29248 · Cited by 22
Zhu, J., Yang, D., Sun, Y., Qiu, X., Chang, H., Li, G., Shan, Y., & Chang, C. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0971 · Cited by 22
Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer
Lu, L., Cole, A. I., Huang, D., Wang, Q., Guo, Z., Yang, W., & Lu, J. Z. (2022) · Biomolecules · doi:10.3390/biom12020203 · Cited by 21
Buhigas, C., Warren, A. Y., Leung, W., Whitaker, H. C., Luxton, H. J., Hawkins, S. F. C., Kay, J. D., Butler, A. P., Xu, Y., Woodcock, D. J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01644-3 · Cited by 21
Self-citationMobashir, M., Turunen, S. P., Izhari, M. A., Ashankyty, I., Helleday, T., & Lehti, K. (2022) · Cells · doi:10.3390/cells11244121 · Cited by 35
Patel, D., Knowell, A. E., Korang‐Yeboah, M., Sharma, P., Joshi, J., Glymph, S., Chinaranagari, S., Nagappan, P., Palaniappan, R., Bowen, N. J., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1100 · Cited by 21
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer
Heath, E. I., Heilbrun, L. K., Smith, D. W., Schopperle, W. M., Ju, Y., Bolton, S., Ahmed, Q. F., & Sakr, W. (2018) · Anticancer Research · doi:10.21873/anticanres.12994 · Cited by 21
miR-484 is associated with disease recurrence and promotes migration in prostate cancer
Lee, D., Tang, W., Dorsey, T. H., & Ambs, S. (2020) · Bioscience Reports · doi:10.1042/bsr20191028 · Cited by 22
Liu, S., Nalesnik, M. A., Singhi, A. D., Wood, M. A., Randhawa, P. S., Ren, B., Humar, A., Liu, P., Yu, Y., Tseng, G. C., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1846 · Cited by 28
Self-citationHEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens
Yeh, I., Song, K. W., Wittmann, B. M., Bai, X., Danielpour, D., & Montano, M. M. (2014) · Biochemical Journal · doi:10.1042/bj20140174 · Cited by 21
Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression
Park, S. H., Tsuzuki, S., Contino, K. F., Ollodart, J., Eber, M. R., Yu, Y., Steele, L. R., Inaba, H., Kamata, Y., Kimura, T., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302041 · Cited by 20
Self-citationYadav, A., Biswas, T., Praveen, A., Ganguly, P., Bhattacharyya, A., Verma, A., Datta, D. B., & Ateeq, B. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0089 · Cited by 20
Shahabi, A., Lewinger, J. P., Ren, J., April, C., Sherrod, A. E., Hacia, J. G., Daneshmand, S., Gill, I. S., Pinski, J., Fan, J., et al. (2016) · The Prostate · doi:10.1002/pros.23211 · Cited by 20
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer
Lü, X., Pan, X., Wu, C., Zhao, D., Feng, S., Zang, Y., Lee, R., Khadka, S., Amin, S. B., Jin, E., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3564 · Cited by 22
Thapa, D., Huang, S., Muñoz, A. R., Yang, X., Bedolla, R. G., Hung, C., Chen, C., Huang, T. H. ‐., Liss, M. A., Reddick, R. L., et al. (2020) · Communications Biology · doi:10.1038/s42003-019-0720-z · Cited by 20
Yi, M., Mudunuri, U. S., Che, A., & Stephens, R. M. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-200 · Cited by 20
Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues
Sircar, K., Gottlieb, B., Alvarado, C., Aprikian, A. G., Beitel, L. K., Alam‐Fahmy, M., Bégin, L. R., & Trifiro, M. A. (2007) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500967 · Cited by 20
De-correlating expression in gene-set analysis
Nam, D. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq380 · Cited by 24
Kissick, H. T., Sanda, M. G., Dunn, L., & Arredouani, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093231 · Cited by 20
Tian, Y., Dong, D., Wang, Z., Wu, L., Park, J. Y., Wei, G., & Wang, L. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.07.003 · Cited by 19
The activity and expression of microRNAs in prostate cancers
Fu, X., Xue, C., Huang, Y., Xie, Y., & Li, Y. (2010) · Molecular BioSystems · doi:10.1039/c0mb00100g · Cited by 21
Wang, G., Haile, S., Comuzzi, B., Tien, A. H., Wang, J., Yong, T. M. K., Jelescu-Bodos, A. E., Blaszczyk, N., Vessella, R. L., Masri, B. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3506 · Cited by 19
Decreased expression of EFS is correlated with the advanced prostate cancer
Sertkaya, S., Hamid, S. M., Dilsiz, N., & Varışlı, L. (2014) · Tumor Biology · doi:10.1007/s13277-014-2703-5 · Cited by 19
Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor
Eisermann, K., Dar, J. A., Dong, J., Wang, D., Masoodi, K. Z., & Wang, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128495 · Cited by 19
Yue, J., Sun, H., Liu, S., Yu, F., Wang, S., Wang, F., Shen, R., Zhu, F., Zhang, L., & Shao, C. (2018) · Cancer Medicine · doi:10.1002/cam4.1532 · Cited by 20
Identifying the role of apolipoprotein A-I in prostate cancer
Wang, J., Xu, L., Liu, C., Huang, T., Liang, C.-Z., & Fan, Y. (2021) · Asian Journal of Andrology · doi:10.4103/aja.aja_92_20 · Cited by 18
Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer
Xie, J., Kusnadi, E. P., Furic, L., & Selth, L. A. (2021) · Cancers · doi:10.3390/cancers13133254 · Cited by 20
Tseng, G. C., Cheng, C., Yu, Y. P., Nelson, J. B., Michalopoulos, G. K., & Luo, J. (2009) · Biomarker Insights · doi:10.4137/bmi.s930 · Cited by 18
Self-citationSerine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer
Zhao, Z., Li, H., Wang, C., Xu, W., Sun, J., & Zhao, W. (2015) · Medical Oncology · doi:10.1007/s12032-015-0524-z · Cited by 18
RNA biomarkers to facilitate the identification of aggressive prostate cancer
Pellegrini, K. L., Sanda, M. G., & Moreno, C. S. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.003 · Cited by 20
Li, J., Hong, Z., Zhang, J., Zheng, S., Wan, F., Liu, Z., & Dai, B. (2024) · Oncogene · doi:10.1038/s41388-024-02945-1 · Cited by 17
Erho, N., Buerki, C., Triche, T. J., Davicioni, E., & Vergara, I. A. (2012) · Journal of Oncology · doi:10.1155/2012/541353 · Cited by 17
Brikun, I. A., Nusskern, D. R., Gillen, D. L., Lynn, A. A. A., Murtagh, D. S., Feczko, J. D., Nelson, W. G., & Freije, D. (2014) · Biomarker Research · doi:10.1186/s40364-014-0025-9 · Cited by 17
Moya, L., Lai, J., Hoffman, A., Srinivasan, S., Panchadsaram, J., Chambers, S. K., Clements, J. A., Batra, J., & BioResource, A. P. C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00428 · Cited by 17
Hong, C., Zhang, F., You, Y., Qiu, W.-L., Giuliano, A. E., Cui, X., Zhang, G., & Cui, Y. (2015) · BMC Cancer · doi:10.1186/s12885-015-1569-2 · Cited by 17
AKAP12α is AssoCiated with Promoter Methylation in Lung Cancer
Jo, U., Whang, Y. M., Kim, H. K., & Kim, Y. H. (2006) · Cancer Research and Treatment · doi:10.4143/crt.2006.38.3.144 · Cited by 17
Murphy, T. M., Sullivan, L., Lane, C., O’Connor, L. M., Barrett, C., Hollywood, D. P., Lynch, T. H., Lawler, M., & Perry, A. S. (2010) · The Prostate · doi:10.1002/pros.21212 · Cited by 17
Shackney, S. E., Chowdhury, S. A., & Schwartz, R. S. (2014) · Cancer Informatics · doi:10.4137/cin.s14062 · Cited by 17
Zuo, Z., Yu, Y. P., Martin, A., & Luo, J. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22494 · Cited by 17
Self-citationCross-platform method for identifying candidate network biomarkers for prostate cancer
Jin, G., Zhou, X., Cui, K., Zhang, X.-S., Chen, L., & Wong, S. T. C. (2009) · IET Systems Biology · doi:10.1049/iet-syb.2008.0168 · Cited by 16
Yu, Y., Liu, S., Geller, D. A., & Luo, J. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.02.017 · Cited by 16
Self-citationInterrogating genomic and epigenomic data to understand prostate cancer
Kim, J., & Yu, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.003 · Cited by 20
Zeng, X., Hu, Z., Wang, Z., Tao, J., Lu, T., Yang, C., Lee, B., & Ye, Z. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.51 · Cited by 16
Lee, D. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9766 · Cited by 16
Creighton, C. J. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-199 · Cited by 17
Systematic Identification and Characterization of RNA Editing in Prostate Tumors
Mo, F., Wyatt, A. W., Sun, Y., Brahmbhatt, S., McConeghy, B. J., Wu, C., Wang, Y. Z., Gleave, M. E., Volik, S. V., & Collins, C. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101431 · Cited by 16
Loss of miR-516a-3p mediates upregulation of ABCC5 in prostate cancer and drives its progression
Zhang, H., Lian, Z., Sun, G., Liu, R., & Xu, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s167463 · Cited by 17
Thymosin β‐NB Is the Human Isoform of Rat Thymosin β15
Banyard, J., Hutchinson, L., & Zetter, B. R. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1415.024 · Cited by 16
Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer
Easwaran, H., & Weeraratna, A. T. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00868-x · Cited by 18
The yin and yang of chromosomal instability in prostate cancer
Carceles‐Cordon, M., Orme, J. J., Domenech, J. M. D., & Rodríguez-Bravo, V. (2024) · Nature Reviews Urology · doi:10.1038/s41585-023-00845-9 · Cited by 15
Pignatta, S., Arienti, C., Zoli, W., Donato, M. D., Castoria, G., Gabucci, E., Casadio, V., Falconi, M., Giorgi, U. D., Silvestrini, R., et al. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.10.022 · Cited by 16
Kela, I., Harmelin, A., Waks, T., Orr‐Urtreger, A., Domany, E., & Eshhar, Z. (2009) · The Prostate · doi:10.1002/pros.20950 · Cited by 15
Tisdale, E. J., Shisheva, A., & Artalejo, C. R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.02.014 · Cited by 15
Molecular Targets for Radiation Oncology in Prostate Cancer
Wang, T., Languino, L. R., Lian, J. B., Stein, G. S., Blute, M. L., & FitzGerald, T. J. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00017 · Cited by 15
RegNetB: Predicting Relevant Regulator-Gene Relationships in Localized Prostate Tumor Samples
Alvarez, A. A., & WOOLF, P. J. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-243 · Cited by 15
SPINT2 Deregulation in Prostate Carcinoma
Pereira, M. S., de Almeida, G. C., Pinto, F., Viana‐Pereira, M., & Reis, R. M. (2015) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415612874 · Cited by 15
Protein tyrosine kinase 6 signaling in prostate cancer.
Alwanian, W. M., & Tyner, A. L. (2020) · PubMed · Cited by 15
Adamo, H. H., Bergström, S. H., & Bergh, A. R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130076 · Cited by 15
Wei, X., Li, X., Pan, Y., Zhang, Y., Zhong, D., Kong, W., Wang, Y., Yu, Z. K., Shao, W., Dong, Y., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03737-5 · Cited by 14
Huang, C., Shen, Q., Song, G., He, S., & Zhou, L. (2021) · Translational Andrology and Urology · doi:10.21037/tau-21-108 · Cited by 14
Podocalyxin in the Diagnosis and Treatment of Cancer
Kelly, M., Michael, R., Marcia, L., Erin, J., Snyder, K., Cipollone, J., Turvey, M. E., Poh, C., McColl, S. R., & Calvin, D. B. W. L. (2012) · InTech eBooks · doi:10.5772/24274 · Cited by 15
Mahat, D. B., Brennan-Laun, S. E., Fialcowitz-White, E. J., Kishor, A., Ross, C. R., Pozharskaya, T., Rawn, J. D., Blackshear, P. J., Hassel, B. A., & Wilson, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033194 · Cited by 14
Use of Genome-Wide High-Throughput Technologies in Biomarker Development
Claßen, S., Staratschek‐Jox, A., & Schultze, J. L. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.5.509 · Cited by 15
DDX52 knockdown inhibits the growth of prostate cancer cells by regulating c-Myc signaling
Yu, W., Ma, H., Li, J., Jin-chao, G., Wang, P., Zhou, Y., Zhang, J., & Shi, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02128-y · Cited by 14
Talantov, D., Jatkoe, T. A., Böhm, M., Zhang, Y., Ferguson, A. M., Stricker, P. D., Kattan, M. W., Sutherland, R. L., Kench, J. G., Wang, Y., et al. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.05.084 · Cited by 14
Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells
He, M., Vanaja, D. K., Karnes, R. J., & Young, C. Y. F. (2009) · The Prostate · doi:10.1002/pros.21013 · Cited by 14
Metadata
- Authors
- Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., & Luo, J.-H.
- Affiliations
- University of Pittsburgh (US)
- From the Department of Pathology and Urology, University of Pittsburgh School of Medicine, and Biostatistics Center, University of Pittsburgh Cancer Institute and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2790-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108426942
- Semantic Scholar
- 8be3bd0e253d2a736b72002f40143dec896e862a
- Cited by
- 758
- References
- 23
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 31 · 2023: 31 · 2022: 20 · 2021: 30 · 2020: 26 · 2019: 29 · 2018: 29 · 2017: 38 · 2016: 24 · 2015: 47 · 2014: 58 · 2013: 41 · 2012: 47
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088110, 1U01 CA 88110-01, R01CA098249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- prostate cancer, gene expression profiling, tumor aggressiveness, prostate carcinogenesis, gene expression patterns
- MeSH terms
- Adult, Cell Transformation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Gene Expression, Disease Progression, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.